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Abstract
Psoriatic arthritis (PsA) is a chronic infl ammatory arthritis associated with psoriasis. It is a member of the spon-
dyloarthritis (SpA) group and its most frequent subtype. It is diffi  cult to determine the epidemiology of PsA due to the 
absence of universally accepted diagnostic criteria. Th e prevalence of PsA among patients with psoriasis is around 30% 
(varying from 6% to 42%). It is higher in Europe and the USA. In Asian countries, the prevalence of PsA among 
 patients with psoriasis has been estimated to be less than 10%. Th ere is still a high prevalence of undiagnosed PsA in 
patients with psoriasis (up to 30%). Dermatologists should be encouraged to regularly screen their patients for PsA 
using several accepted screening tools. Prevalence estimates of PsA in Europe range from 0.05% in Turkey and the 
Czech Republic to 0.42% in Italy. Prevalence estimates of PsA in South America and Asia are lower than in Europe, and 
range from 0.02% in China to 0.07% in Argentina. Th e annual incidence of PsA in patients with psoriasis is 2 to 3%. 
Patients with severe psoriasis and nail changes are at greater risk of developing PsA. Th e fi rst classifi cation criteria for 
PsA were proposed by Moll and Wright in 1973. In 1991, the European Spondyloarthropathy Study Group (ESSG) 
criteria established for the fi rst time that PsA can also occur in the absence of psoriasis. Th e ASAS criteria for axial and 
peripheral SpA can be used in combination for the entire SpA population, including patients with PsA. Th e CASPAR 
criteria, developed by the Group for Research and Assessment of Psoriasis and PsA (GRAPA), have very high specifi c-
ity and sensitivity (98.7% and 91.4%, respectively). Although they are not diagnostic criteria, the CASPAR criteria have 
been accepted not only in research, but in clinical practice as well.
Keywords: Arthritis, psoriatic – classifi cation, diagnosis, epidemiology; Spondylarthritis – classifi cation, diag-
nosis
Sažetak
Psorijatični artritis (PsA) kronični je upalni artritis povezan sa psorijazom i član je grupe spondiloartritisa (SpA) 
te je najčešća podvrsta SpA. Teško je odrediti epidemiologiju PsA zbog nedostatka općeprihvaćenih dijagnostičkih 
kriterija. Prevalencija PsA kod pacijenata sa psorijazom iznosi oko 30% (varira od 6 do 42%). Viša je u Europi i 
SAD-u. U azijskim zemljama prevalencija PsA kod pacijenata sa psorijazom procjenjuje se nižom od 10%. Još i sad se 
često PsA ne dijagnosticira u bolesnika sa psorijazom (do 30%). Stoga dermatologe treba poticati da redovito pregle-
davaju svoje pacijente na PsA koristeći se s nekoliko prihvaćenih alata za probir. Procjene prevalencije PsA u Europi 
kreću se od 0,05% u Turskoj i Češkoj do 0,42% u Italiji. Procjene prevalencije PsA u Južnoj Americi i Aziji niže su nego 
u Europi, kreću se u rasponu od 0,02% u Kini do 0,07% u Argentini. Godišnja incidencija PsA u bolesnika sa psorija-
zom iznosi 2 do 3%. Pacijenti s teškom psorijazom i promjenama nokata imaju viši rizik od razvoja PsA. Prve kriterije 
razvrstavanja za PsA predložili su Moll i Wright 1973. godine. Godine 1991. prvi se put u kriterijima Europske studij-
ske grupe za SpA (ESSG) prepoznalo da se PsA može pojaviti i u odsutnosti psorijaze. Kriteriji ASAS za aksi jalni SpA 
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i periferni SpA mogu se kombinirati u cijeloj populaciji bolesnika sa SpA, uključujući i bolesnike sa PsA. Kriteriji 
CASPAR koje je osmislila grupa za istraživanje i procjenu psorijaze i PsA (GRAPA) pokazuju vrlo visoku specifi čnost 
i osjetljivost (98,7% i 91,4%). Iako nisu dijagnostički kriteriji, kriteriji CASPAR prihvaćeni su ne samo za istraživanja 
nego i za kliničku praksu.
Ključne riječi: Psorijatični artritis – dijagnoza, epidemiologija, klasifi kacija; Spondiloartritis – dijagnoza, klasi-
fi kacija
Introduction
Psoriatic arthritis (PsA) is chronic infl ammatory ar-
thritis associated with psoriasis. Th e manifestation of 
psoriasis usually precedes that of arthritis by 10 years 
on average, although in 20% of cases arthritis and pso-
riasis occur simultaneously, or arthritis precedes the 
skin disease. In this situation, a family history of pso-
riasis is an important clue. Psoriasis may be hidden, so 
it is important to look for psoriatic skin and nail chang-
es in patients with a clinical picture compatible with 
spondyloarthritis (SpA). In most cases of PsA exacer-
bations and remissions of skin and joint disease occur 
with little or no apparent relationship. Around 30 per-
cent of people with psoriasis develop PsA. PsA can 
start slowly with mild symptoms, or it can start quickly 
and be severe. Th e typical clinical presentation shows 
asymmetrical peripheral oligoarthritis or polyarthritis 
with dactylitis and distal interphalangeal joint (DIP) 
involvement. When present, sacroiliitis is usually 
asymmetric, and spondylitis may also be present. 
However, the pattern of disease may change over time. 
Serologically, it is characterized by an absence of rheu-
matoid factor (RF), and radiologically by juxta-articu-
lar new bone formation, absence of periarticular osteo-
penia, and relative preservation of the joint space. PsA 
is a chronic erosive disease and treatments are similar 
to those used in rheumatoid arthritis (RA) (1, 2). PsA 
is a member of the SpA group of chronic inrerrelated 
infl ammatory arthropathies. Th e SpA group includes 
axial SpA with ankylosing spondylitis (AS), peripheral 
SpA, PsA, reactive arthritis (ReA), infl ammatory bow-
el disease-related arthritis, and juvenile spondylo-
arthritis. Common features that link these entities are 
an association with human leukocyte antigen B27 
(HLA-B27), a characteristic pattern of peripheral ar-
thritis that is asymmetric, oligoarticular manifestation 
and predominance in the lower extremities, and pos-
sible sacroiliitis, spondylitis, enthesitis, dactylitis, and 
infl ammatory eye disease (1). Patients with psoriasis 
and PsA more oft en present with comorbidities. Evi-
dence shows an association of psoriasis and PsA with 
depression, metabolic syndrome (central obesity, dys-
lipidemia, hypertension, and insulin resistance), non-
alcoholic fatty liver disease (NAFLD), cardiovascular 
diseases, and osteoporosis. Comorbidities are believed 
to be related to the chronic infl ammation present in 
psoriasis and PsA (3). Despite clinical improvement 
with conventional synthetic disease-modifying anti-
rheumatic drug (csDMARD) treatment, PsA results in 
radiological damage in up to 47% of patients at a me-
dian interval of two years (4). Biologic DMARDs (bD-
MARDs) have been used in the treatment of PsA for 
the last decade (tumor necrosis factor alpha inhibitors 
(TNFi) and the more recently developed anti-interleu-
kin-17 (anti-IL-17)) (5).
History of psoriasis and psoriatic arthritis
Psoriasis is a several-thousand-year-old disease. It 
was discovered on Egyptian mummies. Galen (133–
200 AD) identifi ed psoriasis as a skin disease and was 
the fi rst to call it psoriasis, based on the Greek word 
psora, which means to itch. Psoriasis was believed to be 
contagious, and was confused with leprosy. Th e skele-
tal remains of nine males and one female dating from 
the fi ft h century AD, unearthed in 1983 from the tomb 
of Paulus in the Byzantine monastery of Martyrius in 
the Judean desert, showed visual and radiographic fea-
tures consistent with PsA. Th e presence of these cases 
of PsA within a desert monastery indicates that people 
suff ering from psoriasis used to be isolated (6, 7). In 
the 1840s psoriasis was fi nally distinguished from lep-
rosy. In the 1960s PsA was identifi ed as a specifi c clini-
cal entity (6). Th e fi rst classic description of the clinical 
features of PsA was published in 1973 by Moll and 
Wright (8). Th ey concluded that epidemiological, clin-
ical, radiological, and serological evidence suggests 
that PsA is a specifi c entity rather than the coincidental 
occurrence of two common diseases, psoriasis and RA. 
Th ey defi ned PsA as psoriasis associated with infl am-
matory arthritis (peripheral arthritis and/or spondyli-
tis) with a usually negative serological test for RF. Us-
ing these criteria, Moll and Wright described fi ve sub-
groups of PsA: involvement of DIP joint only, asym-
metrical oligoarthritis, polyarthritis, spondylitis, and 
arthritis mutilans (Table 1).
Epidemiology of psoriatic arthritis
PsA is the most frequent subtype of SpA, followed by 
AS and undiff erentiated spondyloarthritis (USpA) (9). 
PsA usually starts at 30 to 50 years of age, but PsA can 
begin as early as during childhood. Th e mean time be-
tween the occurrence of psoriasis and PsA is 10 years. 
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Th e mean age of psoriasis onset appeared to be similar 
among patients with skin disease alone and in those 
with PsA. In 10 to 15% of patients psoriasis and PsA 
start simultaneously, and in 5–10% of patients PsA ei-
ther starts before skin involvement, or skin involve-
ment does not occur (10, 11, 12). Th e prevalence of 
PsA among patients with psoriasis is around 30% (var-
ying from 6% to 42%) (13, 14). It is higher in Europe 
and the USA. However, in Asian countries, the preva-
lence of PsA among patients with psoriasis has been 
estimated to be less than 10% (15). Th e annual inci-
dence of PsA in patients with psoriasis is 2 to 3%. Pa-
tients with severe psoriasis and nail changes are at 
greater risk of developing PsA (16). A number of stud-
ies have examined the overall prevalence and incidence 
of PsA in countries all over the world. Th e reported 
numbers diff er, depending on the criteria used and the 
geographic region. PsA has an estimated prevalence of 
below 0.5 % in the general population and is generally 
distributed equally across men and women. Prevalence 
and incidence rates of PsA are higher in Europe and 
Northern America than in Asia (Table 2) (17).
Th ere is a trend of rising PsA incidence in some 
countries. Although these fi ndings might be explained 
by an increased awareness of the patients and physi-
cians, there is still a high prevalence of undiagnosed 
PsA in patients with psoriasis (up to 30%) (11, 18). Be-
cause skin psoriasis precedes the onset of PsA in the 
majority of cases, dermatologists have an important 
role in screening psoriasis patients for PsA, especially 
those with rheumatic symptoms. Th ere are several val-
idated screening tools (questionnaires) developed with 
the aim of helping dermatologists and GPs identify pa-
tients who might suff er from PsA: the Psoriasis Epide-
miology Screening Tool (PEST), the Toronto Psoriatic 
Arthritis Screening (ToPAS and ToPAS2), and the Pso-
riatic Arthritis Screening and Evaluation (PASE) ques-
tionnaire. Th ey have comparable sensitivities and spe-
cifi cities (19, 20, 21, 22). PEST is a simple screening 
tool frequently used by non-rheumatologists to screen 
psoriasis patients for signs or symptoms of PsA (21). If 
a total score is indicative of PsA, it is recommended to 
refer these patients to a rheumatologist for further as-
sessment (Table 3).
Th e Toronto Psoriatic Arthritis Screen 2 (ToPAS 2) is 
a screening instrument for identifying PsA both in pa-
tients with psoriasis and in individuals from the gen-
eral population. It includes 13 questions about the pso-
riasis, nail lesions, joint pain and swelling, back pain 
and stiff ness, and dactylitis. Th e questionnaire con-
tains images representing skin and nail lesions, joint 
disease, and dactylitis to help physicians recognize the 
symptoms. It has a specifi city of 82.7% and a sensitivity 
of 87.2% in recognizing patients with PsA (19, 22). In 
real world settings these screening tools seem to have 
insuffi  cient sensitivity but a good specifi city when used 
by dermatologists (23). Despite the insuffi  cient sensi-
tivity of these screening tools, non-rheumatologists 
(GPs and dermatologists) should be encouraged to 
regularly screen their patients for signs or symptoms of 
PsA. It seems that no clinical type of psoriasis is spe-
cifi cally associated with PsA, including pustular psori-
asis of the palms and soles, but patients with psoriasis 
and PsA have more severe skin disease. Rouzaud found 
that there is a trend towards an association between the 
Psoriasis Area and Severity Index (PASI) and the PsA 
risk (mean diff erence 3.39) and a higher frequency of 
nail changes (Odds Ratio (OR) 2.92), particularly 
onycholysis (OR 2.38) (24). Moreover, Rouzaud con-
fi rmed that nail psoriasis is also associated with distal 
interphalangeal joint arthritis. Th erefore, it is recom-
mended that psoriasis patients with such clinical fea-
tures (high PASI score and nail changes) should be 
closely monitored for early detection of PsA (24).
Prevalence estimates of PsA in Europe range from 
0.05% in Turkey and the Czech Republic to 0.42% in 
Italy (Table 2) (25, 26, 27). Prevalence estimates of PsA 
in South America and Asia are lower than in Europe, 
and range from 0.02% in China to 0.07% in Argentina 
(Table 2) (28, 10). Th e prevalence and incidence rates 
of PsA for the year 2002 in Denmark were low. Accord-
ing to the Moll and Wright and CASPAR criteria, the 
prevalences were 0.15% and 0.14%, respectively. Th e 
annual incidence rates based on new self-reported cas-
es in 2002 were 6/100,000 person-years and 11/100,000 
person-years, respectively (29). A recent epidemiologi-
cal study from Denmark revealed a rising trend of PsA 
incidence. Incidence rates of PsA in Denmark in-
creased from 7.3 in 1997 to a peak incidence of 27.3 in 
2010 (per 100,000 person-years). Th ere was a slight 
female predominance ranging from 50.3% (1998) to 
59.2% (2010), and the mean age at the time of diagno-
Table 1 Th e Moll and Wright Criteria for psoriatic arthritis 
proposed in 1973 and fi ve subgroups of psoriatic arthritis 
(modifi ed according to reference No. 8)
Tablica 1. Mollovi i Wrightovi kriteriji za psorijatični artritis 
predloženi 1973. godine i pet oblika psorijatičnog artritisa 
(prilagođeno prema referenciji br. 8)
Moll and Wright Diagnostic Criteria for PsA *
Infl ammatory arthritis (peripheral arthritis and/or sacroiliitis 
or spondylitis)
Presence of psoriasis
Usual absence of serological tests for rheumatoid factor







sensitivity 91%; specifi city 98% / senzitivnost 91%; specifi čnost 98%
Legend: PsA – psoriatic arthritis / psorijatični artritis
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sis was 47–50 years. Incidence rates were highest for 
women and patients aged 50–59 years, respectively 
(18). An epidemiological study on PsA from Reykja-
vik, Iceland, revealed a prevalence of PsA of at least 
0.14%. Th e disease was strikingly more common in 
women. Th e female to male ratio was close to 2:1. Th e 
mean age at skin disease onset was 23 years, with a sig-
nifi cantly earlier onset in women (age 20 years in 
women vs 26 years in men; p = 0.01), but there was no 
signifi cant diff erence for age at the time of onset of 
joint disease (12). Th e annual incidence of PsA in Fin-
land for the year 1995 in the population of 5/21 central 
Table 2 Prevalence and incidence rates of psoriatic arthritis in the general population
Tablica 2. Stope incidencije i prevalencije psorijatičnog artritisa u općoj populaciji
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Sweden 0.25% ND more 
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2007;36(1):14–21. (No. 27)
Turkey 0.05% ND ND Cakır N, Pamuk ÖN, Derviş E, et al. Th e prevalences of some 
rheumatic diseases in western Turkey: Havsa study. Rheumatol Int. 
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Table 4 Amor criteria for the classifi cation 
of spondyloarthropathies published in 1990 
(modifi ed according to reference No. 37)
Tablica 4. Amorovi kriteriji za klasifi kaciju spondiloartritisa 
objavljeni 1990. (prilagođeno prema referenciji br. 37)
Th ere is no entry criterion.
A score of 6 or more classifi es a patient as having SpA. Score
A. Clinical symptoms or history
Lumbar or dorsal pain at night or morning stiff ness 1
Asymmetrical oligoarthritis 2
Buttock pain (alternating buttock pain) 1 (2)
Sausage-like toe or digit 2
Heel pain or other well-defi ned enthesopathy 2
Uveitis 1
Nongonococcal urethritis or cervicitis within 
1 month before the onset of arthritis 1
Acute diarrhea within one month before the onset 
of arthritis 1
Psoriasis, balanitis, or infl ammatory bowel disease 
(ulcerative colitis or Crohn’s disease) 2
B. Radiological fi ndings 
Sacroiliitis (bilateral grade 2 or unilateral grade 3) 3
C. Genetic background
Presence of HLA-B27 and/or family history of 
ankylosing spondylitis, reactive arthritis, uveitis, 
psoriasis, or infl ammatory bowel disease
2
D. Response to treatment
Clear-cut improvement within 48 h aft er NSAIDs 
intake or rapid relapse of the pain aft er their 
discontinuation
2
Legend: SpA – spondyloarthritis / spondiloartritis; NSAID – non-
sterodial anti-infl ammatory drug / nesteroidni protuupalni lijekovi; 
HLA – human leukocyte antigen / HLA – humani leukocitni 
antigen
Table 3 Psoriasis Epidemiology Screening Tool (PEST) 
questionnaire for psoriatic arthritis in patients with psoriasis 
(modifi ed according to reference No. 21)
Tablica 3. Upitnik PEST (engl. Psoriasis Epidemiology 
Screening Tool) probira na psorijatični artritis u bolesnika 
sa psorijazom (prilagođeno prema referenciji br. 21)
Score 1 point for each question answered 
in the affi  rmative.
A total score of 3 or more is indicative of PsA
yes no
Have you ever had a swollen joint (or joints)?
Has a doctor ever told you that you have arthritis?
Do your fi ngernails or toenails have holes or pits?
Have you had pain in your heel?
Have you had a fi nger or toe that was completely 
swollen and painful for no apparent reason?
sensitivity 92%; specifi city 78% / osjetljivost 92%; specifi čnost 78%
Legend: PsA – psoriatic arthritis / psorijatični artritis
hospital districts was 6.1 per 100,000 of the adult pop-
ulation. Th e mean age at diagnosis was 46.8 years. Th e 
peak incidence occurred in the 45–54 year age group. 
Th e male to female ratio was 1.3:1 (30). Savolainen re-
ported a higher incidence of PsA among adults than 
was previously reported from Finland. In this report 
the annual incidence of PsA, in a defi ned population of 
adult inhabitants of Kuopio in the year 2000, was 
23/100,000. Th e mean age at diagnosis was 48.7 years 
(31). In Sweden the prevalence of PsA was estimated at 
0.25%. PsA was more prevalent in women (9). Th e 
Health Improvement Network (THIN) is a large popu-
lation-based medical records database in the UK, and 
is an important resource for the study of PsA. From the 
4.8 million adult patients registered in that database, 
9045 patients had at least one medical code for PsA, 
giving an overall prevalence of 0.19%. Among con-
fi rmed psoriasis patients, the prevalence of PsA was 
8.6%. PsA was more prevalent among patients with se-
vere psoriasis (OR 3.34), obesity (OR 1.77), and dura-
tion of psoriasis for ≥10 years (OR 7.42) in the fully 
adjusted model (32). Th e total annual incidence of PsA 
in the Czech Republic in adults aged 16 years or older 
was 3.6/100,000 and the prevalence of PsA was 0.049% 
(26). Th e fi rst population-based study conducted in 
Italy on a target adult population of 20,882 individuals 
established a very high PsA prevalence of 0.42% (27). 
Th e prevalences of psoriasis and PsA in western Tur-
key were 0.424 % and 0.050%, respectively (25). Th e 
prevalence of PsA among patients with psoriasis is 
relatively higher in Greece compared to other ethnic-
based studies. Th e Greek study included patients with 
psoriasis 52% of which were male and 48% female. 
Th eir median age was 51.41 years, with a median pso-
riasis-presenting age of 34.52 years. Of these patients 
30% had PsA, and among these 51% had psoriatic nail 
disease (33). A large epidemiological study performed 
in Olmsted County, Minnesota, USA, revealed a trend 
of rising PsA incidence and prevalence. Th e PsA inci-
dence cohort comprised 147 adult subjects, of which 
61% were males, with a mean age of 42.7 years. Th e 
overall age- and sex-adjusted annual incidence of PsA 
per 100,000 was 7.2, with a higher incidence in males 
(9.1) than females (5.4). Th e age- and sex-adjusted in-
cidence of PsA per 100,000 increased from 3.6 between 
1970–1979 to 9.8 between 1990–2000 (p for trend 
0.001). Th e point prevalence per 100,000 was 0,158% 
in 2000, with a higher prevalence in males (0.193%) 
than females (0.127%). At incidence, most PsA sub-
jects had oligoarticular involvement (49%) with en-
thesopathy (29%) (11). Th e incidences and prevalences 
of PsA in Buenos Aires, Argentina, and Latin Ameri-
can countries were similar to those reported in other 
studies from Europe and the USA. In the study period, 
138,288 persons contributed a total of 558,878 person-
years, of whom 35 developed PsA (incidence risk-IR 
6.26 cases per 100,000 person-years). Th ere were 12 
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females (IR 3.64 cases per 100,000 person-years) and 
23 males (IR 10.02 cases per 100,000 person-years). In 
January 2006, 65 prevalent cases were identifi ed (prev-
alence 0.074%) (10). Among a Chinese population of 
patients with psoriasis 5.8% had PsA, of which 92% 
were newly diagnosed cases. Compared with patients 
without PsA, patients with PsA had more severe skin 
disease (mean PASI 9.7 vs. 6.0), a higher frequency of 
nail changes (46.4% vs. 21.0%), and scalp involvement 
(90.2% vs. 76.4%). Th e fi ndings are consistent with the 
low prevalence of PsA among patients with psoriasis in 
Asia and confi rm a high percentage of undiagnosed 
cases with active arthritis among PsA patients in der-
matologists’ offi  ces (34). An investigation performed 
in the Han population of Dalang Town, China, con-
fi rmed a low prevalence of PsA in China (0.022%.) 
(28). Although many studies have indicated a low 
prevalence rate of PsA in patients with psoriasis in the 
Japanese population, the rate is gradually increasing 
every year and is estimated to be over 10% . In Japan, 
Table 5 European Spondyloarthropathy Study Group (ESSG) 
criteria for the classifi cation of the spondyloarthropathy group 
as a whole published in 1991 (modifi ed according to reference 
No. 38)
Tablica 5. Klasifi kacijski kriteriji općenito za grupu 
spondiloartritisa doneseni od Europske grupe za istraživanje 





or Synovitis asymmetric or predominantly 
in the lower limbs
And one or more of the following:
Positive family 
history
Presence in fi rst-degree or second-degree 
relatives of any of the following: 
ankylosing spondylitis, psoriasis, acute 
uveitis, reactive arthritis, infl ammatory 
bowel disease
Infl ammatory bowel 
disease
Past or present Crohn’s disease 
or ulcerative colitis diagnosed by a 
physician and confi rmed by radiographic 
examination or endoscopy
Psoriasis Past or present psoriasis diagnosed by 
a physician
Urethritis, cervicitis, 
or acute diarrhea 
within one month 
before arthritis
Episode of diarrhea occurring within 
one month before arthritis
Nongonococcal urethritis or cervicitis 




right and left  gluteal 
areas
Past or present pain alternating between 
the right and left  gluteal regions
Sacroiliitis Bilateral grade 2–4 or unilateral grade 
3–4, according to the following 
radiographic grading system: 0 = normal, 
1 = possible, 2 = minimal, 3 = moderate, 
and 4 = ankylosis
Enthesopathy Past or present spontaneous pain or 
tenderness at examination of the site of 
the insertion of the Achilles tendon or 
plantar fascia
sensitivity 87%; specifi city 87% / osjetljivost 87%; specifi čnost 87%
Table 6 Assessment of SpondyloArthritis international 
Society (ASAS) classifi cation criteria for axial 
spondyloarthritis (SpA) published in 2009 (modifi ed 
according to references No. 40 and 41)
Tablica 6. Kriteriji Međunarodnog društva za mjerenja 
u spondiloartritisu (ASAS) za aksijalni spondiloartritis 
(SpA) objavljeni 2009. 
(prilagođeno prema referencijama br. 40 i 41)
Entry criteria:
Patient with chronic back pain (≥3 months) and age at onset 
of back pain < 45 years
or
Sacroiliitis on imaging plus ≥1 
SpA feature: 
HLA-B27 plus ≥2 other SpA 
features: 
SpA features : Sacroiliitis on imaging (radiographs or MRI):
Infl ammatory back pain** Active (acute) infl ammation 
on MRI highly suggestive on 
sacroiliitis associated with SpA*#
Arthritis Defi nite radiographic 
sacroiliitis according to 






Good response to NSAIDs
Positive family history for SpA
HLA-B27 
Elevated CRP
sensitivity 82.9%; specifi city 84.4% 
/ Osjetljivost 82,9%; specifi čnost 84,4%
*Active infl ammatory lesions on MRI (STIR/post-gadolinium T1): 
bone marrow edema (osteitis), capsulitis, synovitis, enthesitis. 
/ Aktivne upalne promjene (STIR/post-gadolinij T1): 
edem koštane srži (osteitis), kapsulitis, sinovitis, entezitis.
** Th e ASAS criteria for infl ammatory back pain are fulfi lled if at 
least four out of fi ve parameters are present: age at onset <40 years, 
insidious onset, improvement with exercise, no improvement with 
rest, pain at night (with improvement upon getting up). / Kriteriji 
ASAS-a za upalnu bol u leđima ispunjeni su ako su prisutna 
najmanje četiri od pet parametara: dob pri nastupu križobolje < 40 
godina, podmukao nastup, poboljšanje vježbanjem, bez poboljšanja 
s odmaranjem, bol noću (uz poboljšanje nakon ustajanja).
#Chronic infl ammatory lesions on MRI (normally T1): sclerosis, 
erosions, fat deposition, bony bridges/ankylosis. / Kronične upalne 
promjene (obično T1): skleroza, erozije, masna degeneracija, 
koštana premoštenja/ankiloza.
Legend: SpA – spondyloarthritis / spondiloartritis; MRI – magnetic 
resonance imaging / magnetska rezonancija; HLA – human 
leukocyte antigen / humani leukocitni antigen; IBD – infl ammatory 
bowel disease / upalna bolest crijeva; CRP – C-reactive protein / 
C-reaktivni protein; NSAID – nonsterodial anti-infl ammatory drug 
/ nesteroidni protuupalni lijekovi
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there was a male predominance. Th e mean onset age of 
PsA was 45 years, and the mean onset age for cutane-
ous psoriasis was under 36 years. Th e mean time be-
tween the occurrence of psoriasis and PsA was 11.2 
years, whereas that in patients in whom psoriasis was 
preceded by arthritis was 4.4 years. Th e polyarthritis 
type was most common (36%), followed by the distal 
interphalangeal (26%) and oligoarthritis (22%) types. 
Back pain was present in 34.3% of patients. Enthesitis 
and dactylitis were observed in 28.3% and 59.2%, re-
spectively (35).
Diagnostic and classifi cation criteria 
for psoriatic arthritis
Aggarwal defi ned the diagnostic and classifi cation 
criteria and pointed out the main diff erences between 
them (36).
Diagnostic criteria are a set of signs, symptoms, and 
tests designed for use in routine clinical settings to 
guide the physicians in care of the individual patient. 
Th ey must refl ect all the diff erent features of a disease, 
and be able to accurately identify as many individuals 
with the condition as possible. Th ere are only a few 
validated diagnostic criteria in rheumatology (36). As 
PsA is very heterogeneous disease, the clinical picture 
may change over the disease course in an individual 
patient, and there is no golden diagnostic standard for 
PsA. Th at is why diagnostic criteria for PsA have not 
yet been developed and validated.
Classifi cation criteria are primarily intended to cre-
ate defi ned cohorts for clinical research. When used in 
clinical settings they cannot capture all patients with a 
specifi c disease, but rather the majority of patients with 
shared key features. Classifi cation criteria have a high 
specifi city with a somewhat lower sensitivity (36). Only 
physicians considering the features of individual pa-
tients (regardless of the classifi cation criteria) can es-
tablish a diagnosis for an individual patient.
Th e fi rst classifi cation criteria for PsA were proposed 
by Moll and Wright in 1973. Th ey are the oldest and 
most widely known guide to diagnosing psoriatic ar-
thritis (8). SpA was formally classifi ed in the Amor cri-
teria in 1990 (Table 4).
Th e Amor criteria are a list of signs based on a scor-
ing system of laboratory, radiological, and clinical fea-
tures and do not require an entry criterion. Although 
sacroiliitis is not mandatory for the diagnosis of SpA 
when using the Amor criteria, it has the highest score 
and is considered to be very specifi c for SpA (37). In 
1991, Th e European Spondyloarthropathy Study Goup 
(ESSG) derived classifi cation criteria intended to cap-
ture a wide spectrum of SpA (seronegative oligoarthri-
tis, dactylitis or polyarthritis of the lower extremities, 
heel pain due to enthesitis). Although the intention of 
the criteria was aimed at a diagnostic classifi cation of 
the SpA group as a whole, particular types of SpA, in-
cluding PsA, can be identifi ed from the published clas-
sifi cation criteria as well (Table 5). For the fi rst time, it 
was recognized that PsA can actually also occur in the 
absence of psoriasis (38). In 1999, McGonagle pro-
posed a defi nition of PsA based on enthesopathy, ex-
plaining the wide clinical picture of PsA in terms of 
enthesitis. McGonagle divided the wide clinical spec-
trum of PsA into common arthropathies (polyarthritis, 
spinal infl ammation, peripheral enthesitis, distal inter-
phalangeal joint arthritis, monoarthritis/oligoarthritis, 
dactylitis-sausage digits), uncommon arthropathies 
(palmar plantar pustulosis, synovitis, acne, pustulosis, 
hyperostosis, and osteolysis – SAPHO syndrome, 
spondylodiscitis, arthritis mutilans, onycho-pachyder-
mo-periostitis, chronic multifocal recurrent osteomy-
elitis), and other features (arthralgia, chest pain). Th ere 
is a signifi cant problem with evaluation of the original 
McGonagle criteria set because of magnetic resonance 
imaging (MRI) requirements. Perhaps that is the rea-
son they are not widely used. Nowadays it is likely that 
ultrasonographic evidence of enthesopathy might 
 substitute MRI (39). In 2009, the Assessment of Spon-
dyloArthritis international Society (ASAS) derived 
the classifi cation criteria for axial SpA, and in 2011 
the classifi cation criteria for peripheral SpA (Table 6, 
Table 7).
Th e ASAS criteria for axial SpA and peripheral SpA 
can be used in combination among the entire SpA pop-
Table 7 Assessment of SpondyloArthritis international 
Society (ASAS) classifi cation criteria for peripheral 
spondyloarthritis (SpA) published in 2011 
(modifi ed according to reference No. 42)
Tablica 7. Kriteriji Međunarodnog društva za mjerenja 
u spondiloartritisu (ASAS) za periferni spondiloartritis (SpA) 
objavljeni 2011. (prilagođeno prema referenciji br. 42)
Entry criterion:
Arthritis or enthesitis or dactylitis
or
plus ≥1 of: plus ≥2 of the remaining: 
Psoriasis Arthritis




HLA-B27 IBP in the past
Uveitis Positive family history for SpA
Sacroiliitis on imaging 
(radiographs or MRI)
sensitivity 77.8%; specifi city 82.2% 
/ Osjetljivost 77,8%; specifi čnost 82,2%
Legend: MRI – magnetic resonance imaging / magnetska rezonan-
cija; HLA – human leukocyte antigen / humani leukocitni antigen; 
IBD – infl ammatory bowel disease / upalna bolest crijeva; 
SpA – spondyloarthritis / spondiloartritis
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ulation, including patients with PsA. In patients with 
predominantly axial involvement (back pain), with or 
without peripheral manifestations, the ASAS criteria 
for axial SpA should be applied. Th e criteria for pe-
ripheral SpA are applicable to patients with peripheral 
arthritis (usually predominantly of the lower limbs 
and/or asymmetric arthritis), and/or enthesitis, and/or 
dactylitis. In the entire SpA population, sensitivity and 
specifi city of the combined use of the two sets of crite-
ria is 79.5% and 83.3%, respectively (40, 41, 42). Th e 
classifi cation for psoriatic arthritis criteria (CASPAR 
criteria) were published in 2006 (Table 8). Th ey were 
developed by the Group for Research and Assessment 
of Psoriasis and PsA (GRAPPA). Th e CASPAR criteria 
are easy to use in epidemiological studies. Th e specifi c-
ity and sensitivity of these criteria is very high (98.7% 
and 91.4%, respectively). Although they are not diag-
nostic criteria, the CASPAR criteria have been gaining 
acceptance in both research and clinical practice (43).
Conclusion
As the diagnostic criteria for psoriatic arthritis have 
not been validated, it is diffi  cult to determine the epi-
demiology of PsA due to the absence of universally ac-
cepted diagnostic criteria. Most patients with a clinical 
diagnosis of SpA fulfi ll several classifi cation criteria 
sets at the same time (44). Th e CASPAR classifi cation 
criteria for PsA, developed in 2006 by the GRAPPA, 
defi ne PsA for the purpose of enrolling patients in clin-
ical trials, but these classifi cation criteria, due to their 
very high sensitivity and specifi city, can also provide 
guidance to physicians for diagnosing PsA in everyday 
clinical practice.
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